

Table of Contents

| Number | Title |
|--------|--|
| 1 | Table 00: Comments |
| 2 | Table 01: Study population and enrolment information |
| 3 | Table 02: Patients by region, country, and cohort |
| 4 | Table 03 : Demographic Characteristics |
| 5 | Table 04 : Care setting , Type of AF and Insurance |
| 6 | Table 05 : Vital signs and life style |
| 7 | Table 06 : Clinical History |
| 8 | Table 07 : Treatment for stroke prophylaxis |
| 9 | Table 08: Treatment |
| 10 | Table 09 : Risk scores |
| 11 | Table 10: Treatment at baseline by CHA2DS2-VASc score |
| 12 | Table 11: Treatment at baseline by HAS-BLED score |
| 13 | Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4 |
| 14 | Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4 |
| 15 | Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4 |
| 16 | Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4 |
| 17 | Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4 |
| 18 | Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4 |
| 19 | Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4 |

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

**Table 01: Study population and enrolment information
Full Analysis Dataset : SPAIN**

| | |
|--|-----------------------|
| Number of prospective patients (C1+C2+C3+C4+C5) | 2421 |
| Number of enrolling sites | 39 |
| Number of enrolling countries | 1 |
| Enrolment period | 20SEP2010 - 22JUL2016 |
| Duration of enrolment (months) | 70.1 |

**Table 02: Patients by region, country, and cohort
Full Analysis Dataset : SPAIN**

| Region | Country | Cohort 1 Retrospective patients (N=351) | Cohort 1 Prospective patients (N=450) | Cohort 2 (N=617) | Cohort 3 (N=558) | Cohort 4 (N=461) | Cohort 5 (N=335) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------|----------------|--|--|-----------------------------|-----------------------------|-----------------------------|-----------------------------|---|---|
| Europe | Spain | 351 | 450 | 617 | 558 | 461 | 335 | 2421 | 2086 |

**Table 03 : Demographic Characteristics
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------------------------------|-----------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Sex, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Male | 197 (56.1) | 228 (50.7) | 321 (52.0) | 275 (49.3) | 254 (55.1) | 178 (53.1) | 1256 (51.9) | 1078 (51.7) |
| | Female | 154 (43.9) | 222 (49.3) | 296 (48.0) | 283 (50.7) | 207 (44.9) | 157 (46.9) | 1165 (48.1) | 1008 (48.3) |
| Age at Diagnosis (Years) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Mean (SD) | 71.5 (9.8) | 72.8 (11.4) | 73.2 (10.6) | 73.8 (9.8) | 74.0 (10.2) | 75.0 (10.1) | 73.7 (10.4) | 73.5 (10.5) |
| | Median (IQR) | 73.0 (65.0 to 79.0) | 75.0 (65.0 to 81.0) | 75.0 (66.0 to 81.0) | 75.0 (68.0 to 81.0) | 76.0 (67.0 to 81.0) | 76.0 (69.0 to 83.0) | 75.0 (67.0 to 81.0) | 75.0 (67.0 to 81.0) |
| | Min to Max | 40 to 93 | 31 to 101 | 35 to 98 | 38 to 99 | 39 to 101 | 42 to 94 | 31 to 101 | 31 to 101 |
| Age Group, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | <65 | 84 (23.9) | 103 (22.9) | 127 (20.6) | 91 (16.3) | 72 (15.6) | 48 (14.3) | 441 (18.2) | 393 (18.8) |
| | 65-74 | 125 (35.6) | 121 (26.9) | 177 (28.7) | 172 (30.8) | 141 (30.6) | 102 (30.4) | 713 (29.5) | 611 (29.3) |
| | >=75 | 142 (40.5) | 226 (50.2) | 313 (50.7) | 295 (52.9) | 248 (53.8) | 185 (55.2) | 1267 (52.3) | 1082 (51.9) |
| Time since AF Diagnosis (Weeks) | n (missing) | 351 (0) | 332 (118) | 414 (203) | 403 (155) | 351 (110) | 250 (85) | 1750 (671) | 1500 (586) |
| | Mean (SD) | 61.26 (24.11) | 2.67 (1.94) | 2.35 (1.79) | 2.39 (1.87) | 2.34 (1.76) | 2.28 (1.68) | 2.41 (1.82) | 2.43 (1.84) |
| | Median (IQR) | 58.40 (39.50 to 81.80) | 2.50 (0.90 to 4.50) | 2.00 (0.80 to 4.00) | 2.00 (0.70 to 4.10) | 2.00 (0.70 to 4.00) | 2.10 (0.80 to 3.50) | 2.00 (0.80 to 4.00) | 2.00 (0.80 to 4.10) |
| | Min to Max | 26.1 to 104.2 | 0.1 to 6.0 | 0.1 to 6.0 | 0.1 to 6.0 | 0.1 to 6.0 | 0.1 to 6.0 | 0.1 to 6.0 | 0.1 to 6.0 |
| Race, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Caucasian | 313 (89.2) | 414 (92.0) | 577 (93.5) | 532 (95.3) | 429 (93.1) | 275 (82.1) | 2227 (92.0) | 1952 (93.6) |
| | Hispanic/Latino | 34 (9.7) | 33 (7.3) | 39 (6.3) | 25 (4.5) | 32 (6.9) | 58 (17.3) | 187 (7.7) | 129 (6.2) |
| | Afro-Caribbean | 1 (0.3) | - | - | - | - | - | - | - |

**Table 03 : Demographic Characteristics
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|--------------|---------------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| | Asian (Not Chinese) | 1 (0.3) | 2 (0.4) | - | - | - | - | 2 (0.1) | 2 (0.1) |
| | Chinese | 2 (0.6) | - | - | - | - | 1 (0.3) | 1 (0.0) | - |
| | Mixed/Other | - | 1 (0.2) | 1 (0.2) | 1 (0.2) | - | 1 (0.3) | 4 (0.2) | 3 (0.1) |
| Region, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Europe | 351 (100.0) | 450 (100.0) | 617 (100.0) | 558 (100.0) | 461 (100.0) | 335 (100.0) | 2421 (100.0) | 2086 (100.0) |

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|--|---|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Care Setting Speciality at Diagnosis, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Internal Medicine | 49 (14.0) | 99 (22.0) | 152 (24.6) | 87 (15.6) | 54 (11.7) | 47 (14.0) | 439 (18.1) | 392 (18.8) |
| | Cardiology | 189 (53.8) | 228 (50.7) | 270 (43.8) | 291 (52.2) | 232 (50.3) | 181 (54.0) | 1202 (49.6) | 1021 (48.9) |
| | Neurology | 8 (2.3) | 7 (1.6) | 15 (2.4) | 18 (3.2) | 19 (4.1) | 2 (0.6) | 61 (2.5) | 59 (2.8) |
| | Geriatrics | 2 (0.6) | 2 (0.4) | 3 (0.5) | 2 (0.4) | 4 (0.9) | 1 (0.3) | 12 (0.5) | 11 (0.5) |
| | Primary Care/General Practice | 103 (29.3) | 114 (25.3) | 177 (28.7) | 160 (28.7) | 152 (33.0) | 104 (31.0) | 707 (29.2) | 603 (28.9) |
| Care Setting Location at Diagnosis, n(%) | n (missing) | 346 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Hospital | 131 (37.9) | 123 (27.3) | 221 (35.8) | 240 (43.0) | 183 (39.7) | 132 (39.4) | 899 (37.1) | 767 (36.8) |
| | Office | 146 (42.2) | 143 (31.8) | 180 (29.2) | 175 (31.4) | 168 (36.4) | 144 (43.0) | 810 (33.5) | 666 (31.9) |
| | Anticoagulation clinic/thrombosi s centre | 5 (1.4) | 1 (0.2) | 17 (2.8) | 1 (0.2) | 1 (0.2) | - | 20 (0.8) | 20 (1.0) |
| | Emergency room | 64 (18.5) | 183 (40.7) | 199 (32.3) | 142 (25.4) | 109 (23.6) | 59 (17.6) | 692 (28.6) | 633 (30.3) |
| | Unknown | 5 | - | - | - | - | - | - | - |
| Type of AF Diagnosed, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | Permanent | 140 (39.9) | 70 (15.6) | 114 (18.5) | 59 (10.6) | 94 (20.4) | 58 (17.3) | 395 (16.3) | 337 (16.2) |
| | Persistent | 57 (16.2) | 84 (18.7) | 90 (14.6) | 134 (24.0) | 111 (24.1) | 71 (21.2) | 490 (20.2) | 419 (20.1) |
| | Paroxysmal | 106 (30.2) | 82 (18.2) | 128 (20.7) | 106 (19.0) | 107 (23.2) | 80 (23.9) | 503 (20.8) | 423 (20.3) |
| | New | 48 (13.7) | 214 (47.6) | 285 (46.2) | 259 (46.4) | 149 (32.3) | 126 (37.6) | 1033 (42.7) | 907 (43.5) |

**Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------------------|--------------------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Treatment Costs, n(%) | n (missing) | 2 (0) | 1 (0) | 330 (0) | 557 (0) | 452 (0) | 335 (0) | 1675 (0) | 1340 (0) |
| | Public insurance | 2 (100.0) | 1 (100.0) | 315 (95.5) | 541 (97.1) | 402 (88.9) | 286 (85.4) | 1545 (92.2) | 1259 (94.0) |
| | Private (insurance) | - | - | 4 (1.2) | 3 (0.5) | 35 (7.7) | 43 (12.8) | 85 (5.1) | 42 (3.1) |
| | Combination | - | - | 11 (3.3) | 13 (2.3) | 15 (3.3) | 6 (1.8) | 45 (2.7) | 39 (2.9) |
| | Unknown | 349 | 449 | 287 | 1 | 9 | - | 746 | 746 |
| Treatment Sector, n(%) | n (missing) | 2 (0) | 1 (0) | 331 (0) | 558 (0) | 461 (0) | 335 (0) | 1686 (0) | 1351 (0) |
| | In the public sector | 2 (100.0) | 1 (100.0) | 320 (96.7) | 541 (97.0) | 403 (87.4) | 287 (85.7) | 1552 (92.1) | 1265 (93.6) |
| | In the private sector | - | - | 11 (3.3) | 17 (3.0) | 58 (12.6) | 48 (14.3) | 134 (7.9) | 86 (6.4) |
| | Unknown | 349 | 449 | 286 | - | - | - | 735 | 735 |

Table 05 : Vital signs and life style
Full Analysis Dataset : SPAIN

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|--------------------------|--------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Height (cm) | n (missing) | 290 (61) | 401 (49) | 408 (209) | 364 (194) | 305 (156) | 247 (88) | 1725 (696) | 1478 (608) |
| | Mean (SD) | 163.5 (9.4) | 163.3 (10.1) | 162.7 (9.2) | 161.9 (9.3) | 163.5 (10.6) | 163.5 (9.7) | 162.9 (9.8) | 162.8 (9.8) |
| | Median (IQR) | 163.0 (157.0 to 170.0) | 164.0 (156.0 to 170.0) | 163.0 (156.0 to 170.0) | 162.0 (155.0 to 168.0) | 163.0 (156.0 to 170.0) | 165.0 (157.0 to 170.0) | 163.0 (156.0 to 170.0) | 163.0 (156.0 to 170.0) |
| | Min to Max | 141 to 185 | 140 to 191 | 135 to 190 | 130 to 190 | 137 to 193 | 135 to 190 | 130 to 193 | 130 to 193 |
| Weight (kg) | n (missing) | 290 (61) | 401 (49) | 408 (209) | 364 (194) | 305 (156) | 247 (88) | 1725 (696) | 1478 (608) |
| | Mean (SD) | 78.4 (14.4) | 78.2 (15.3) | 77.5 (15.2) | 76.4 (15.9) | 78.3 (16.0) | 78.3 (16.3) | 77.7 (15.7) | 77.6 (15.6) |
| | Median (IQR) | 76.5 (69.0 to 86.0) | 78.0 (68.0 to 87.0) | 78.0 (67.0 to 86.0) | 75.0 (66.0 to 84.0) | 76.0 (67.0 to 87.0) | 78.0 (68.0 to 89.0) | 77.0 (67.0 to 86.0) | 76.0 (67.0 to 86.0) |
| | Min to Max | 47 to 125 | 40 to 160 | 40 to 137 | 44 to 150 | 45 to 147 | 45 to 124 | 40 to 160 | 40 to 160 |
| BMI (kg/m ²) | n (missing) | 290 (61) | 401 (49) | 408 (209) | 364 (194) | 305 (156) | 247 (88) | 1725 (696) | 1478 (608) |
| | Mean (SD) | 29.4 (5.0) | 29.3 (4.8) | 29.2 (4.9) | 29.1 (5.2) | 29.3 (5.2) | 29.2 (5.2) | 29.2 (5.0) | 29.2 (5.0) |
| | Median (IQR) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) | 29.0 (26.0 to 32.0) |
| | Min to Max | 17 to 49 | 19 to 50 | 16 to 49 | 17 to 52 | 18 to 51 | 19 to 52 | 16 to 52 | 16 to 52 |
| BMI Category, n(%) | n (missing) | 290 (61) | 401 (49) | 408 (209) | 364 (194) | 305 (156) | 247 (88) | 1725 (696) | 1478 (608) |
| | <19 | 1 (0.3) | - | 4 (1.0) | 4 (1.1) | 2 (0.7) | - | 10 (0.6) | 10 (0.7) |
| | 19-<25 | 45 (15.5) | 73 (18.2) | 62 (15.2) | 72 (19.8) | 59 (19.3) | 49 (19.8) | 315 (18.3) | 266 (18.0) |
| | 25-<30 | 137 (47.2) | 162 (40.4) | 175 (42.9) | 149 (40.9) | 130 (42.6) | 100 (40.5) | 716 (41.5) | 616 (41.7) |
| | 30-<40 | 94 (32.4) | 158 (39.4) | 155 (38.0) | 129 (35.4) | 102 (33.4) | 93 (37.7) | 637 (36.9) | 544 (36.8) |
| | >=40 | 13 (4.5) | 8 (2.0) | 12 (2.9) | 10 (2.7) | 12 (3.9) | 5 (2.0) | 47 (2.7) | 42 (2.8) |
| Pulse (bpm) | n (missing) | 290 (61) | 425 (25) | 530 (87) | 518 (40) | 415 (46) | 298 (37) | 2186 (235) | 1888 (198) |
| | Mean (SD) | 85.4 (27.0) | 92.5 (27.4) | 99.2 (31.6) | 94.9 (28.1) | 93.5 (28.1) | 91.5 (28.0) | 94.7 (28.9) | 95.2 (29.0) |
| | Median (IQR) | 79.0 (65.0 to 100.0) | 85.0 (72.0 to 114.0) | 94.0 (75.0 to 128.0) | 90.0 (72.0 to 114.0) | 88.0 (73.0 to 110.0) | 87.0 (70.0 to 110.0) | 90.0 (72.0 to 115.0) | 90.0 (72.0 to 116.0) |
| | Min to Max | 44 to 170 | 42 to 167 | 40 to 190 | 40 to 170 | 34 to 200 | 30 to 164 | 30 to 200 | 34 to 200 |

**Table 05 : Vital signs and life style
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------------------------------|--------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Systolic BP (mm Hg) | n (missing) | 321 (30) | 431 (19) | 546 (71) | 495 (63) | 406 (55) | 275 (60) | 2153 (268) | 1878 (208) |
| | Mean (SD) | 134.6 (21.5) | 136.6 (21.0) | 136.9 (21.0) | 137.6 (21.3) | 137.2 (18.7) | 136.4 (20.2) | 137.0 (20.6) | 137.1 (20.6) |
| | Median (IQR) | 134.0 (120.0 to 146.0) | 135.0 (123.0 to 150.0) | 136.0 (121.0 to 150.0) | 135.0 (123.0 to 149.0) | 138.0 (126.0 to 150.0) | 135.0 (122.0 to 149.0) | 136.0 (123.0 to 150.0) | 136.0 (123.0 to 150.0) |
| | Min to Max | 80 to 221 | 40 to 202 | 64 to 220 | 75 to 219 | 89 to 210 | 83 to 220 | 40 to 220 | 40 to 220 |
| Diastolic BP (mm Hg) | n (missing) | 321 (30) | 431 (19) | 546 (71) | 495 (63) | 406 (55) | 275 (60) | 2153 (268) | 1878 (208) |
| | Mean (SD) | 78.6 (13.0) | 79.0 (13.6) | 80.2 (13.4) | 80.4 (15.2) | 79.9 (13.4) | 78.1 (13.4) | 79.7 (13.9) | 79.9 (14.0) |
| | Median (IQR) | 79.0 (70.0 to 87.0) | 80.0 (70.0 to 88.0) | 80.0 (70.0 to 90.0) | 80.0 (70.0 to 90.0) | 80.0 (70.0 to 89.0) | 78.0 (70.0 to 87.0) | 80.0 (70.0 to 89.0) | 80.0 (70.0 to 90.0) |
| | Min to Max | 40 to 131 | 26 to 122 | 30 to 150 | 36 to 130 | 40 to 120 | 30 to 127 | 26 to 150 | 26 to 150 |
| LVEF (%) | n (missing) | 192 (159) | 206 (244) | 234 (383) | 280 (278) | 199 (262) | 141 (194) | 1060 (1361) | 919 (1167) |
| | Mean (SD) | 61.5 (12.7) | 60.5 (13.7) | 57.9 (13.6) | 58.8 (13.3) | 59.9 (13.2) | 61.2 (12.6) | 59.4 (13.4) | 59.2 (13.5) |
| | Median (IQR) | 62.0 (55.0 to 70.0) | 65.0 (55.0 to 70.0) | 60.0 (50.0 to 67.0) | 60.0 (54.5 to 67.0) | 63.0 (55.0 to 68.0) | 65.0 (57.0 to 69.0) | 62.0 (55.0 to 68.0) | 61.0 (53.0 to 68.0) |
| | Min to Max | 15 to 100 | 20 to 90 | 15 to 87 | 11 to 84 | 15 to 82 | 20 to 88 | 11 to 90 | 11 to 90 |
| LVEF Category, n (missing) n(%) | n (missing) | 192 (159) | 206 (244) | 234 (383) | 280 (278) | 199 (262) | 141 (194) | 1060 (1361) | 919 (1167) |
| | <40% | 11 (5.7) | 21 (10.2) | 23 (9.8) | 27 (9.6) | 19 (9.5) | 10 (7.1) | 100 (9.4) | 90 (9.8) |
| | >=40% | 181 (94.3) | 185 (89.8) | 211 (90.2) | 253 (90.4) | 180 (90.5) | 131 (92.9) | 960 (90.6) | 829 (90.2) |
| History of Hypertension, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 557 (0) | 461 (0) | 335 (0) | 2420 (0) | 2085 (0) |
| | No | 81 (23.1) | 115 (25.6) | 138 (22.4) | 130 (23.3) | 112 (24.3) | 74 (22.1) | 569 (23.5) | 495 (23.7) |
| | Yes | 270 (76.9) | 335 (74.4) | 479 (77.6) | 427 (76.7) | 349 (75.7) | 261 (77.9) | 1851 (76.5) | 1590 (76.3) |

Table 05 : Vital signs and life style
Full Analysis Dataset : SPAIN

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------------------------|----------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| | Unknown | - | - | - | 1 | - | - | 1 | 1 |
| Alcohol Consumption, n(%) | n (missing) | 331 (0) | 422 (0) | 553 (0) | 463 (0) | 407 (0) | 290 (0) | 2135 (0) | 1845 (0) |
| | Abstinent | 248 (74.9) | 325 (77.0) | 432 (78.1) | 355 (76.7) | 307 (75.4) | 215 (74.1) | 1634 (76.5) | 1419 (76.9) |
| | Light | 72 (21.8) | 78 (18.5) | 76 (13.7) | 82 (17.7) | 71 (17.4) | 55 (19.0) | 362 (17.0) | 307 (16.6) |
| | Moderate | 11 (3.3) | 12 (2.8) | 35 (6.3) | 19 (4.1) | 21 (5.2) | 13 (4.5) | 100 (4.7) | 87 (4.7) |
| | Heavy | - | 7 (1.7) | 10 (1.8) | 7 (1.5) | 8 (2.0) | 7 (2.4) | 39 (1.8) | 32 (1.7) |
| | Unknown | 20 | 28 | 64 | 95 | 54 | 45 | 286 | 241 |
| Smoker, n(%) | n (missing) | 339 (0) | 436 (0) | 575 (0) | 486 (0) | 435 (0) | 310 (0) | 2242 (0) | 1932 (0) |
| | No | 222 (65.5) | 309 (70.9) | 388 (67.5) | 343 (70.6) | 304 (69.9) | 233 (75.2) | 1577 (70.3) | 1344 (69.6) |
| | Ex-smoker | 93 (27.4) | 99 (22.7) | 137 (23.8) | 102 (21.0) | 97 (22.3) | 54 (17.4) | 489 (21.8) | 435 (22.5) |
| | Current smoker | 24 (7.1) | 28 (6.4) | 50 (8.7) | 41 (8.4) | 34 (7.8) | 23 (7.4) | 176 (7.9) | 153 (7.9) |
| | Unknown | 12 | 14 | 42 | 72 | 26 | 25 | 179 | 154 |

Table 06 : Clinical History
Full Analysis Dataset : SPAIN

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---|-------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Congestive heart failure, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | No | 303 (86.3) | 357 (79.3) | 512 (83.0) | 508 (91.0) | 423 (91.8) | 302 (90.1) | 2102 (86.8) | 1800 (86.3) |
| | Yes | 48 (13.7) | 93 (20.7) | 105 (17.0) | 50 (9.0) | 38 (8.2) | 33 (9.9) | 319 (13.2) | 286 (13.7) |
| Congestive Heart Failure NYHA Class, n(%) | n (missing) | 47 (303) | 93 (357) | 99 (512) | 43 (508) | 35 (423) | 29 (302) | 299 (2102) | 270 (1800) |
| | I | 13 (27.7) | 19 (20.4) | 23 (23.2) | 10 (23.3) | 8 (22.9) | 4 (13.8) | 64 (21.4) | 60 (22.2) |
| | II | 28 (59.6) | 47 (50.5) | 44 (44.4) | 25 (58.1) | 18 (51.4) | 22 (75.9) | 156 (52.2) | 134 (49.6) |
| | III | 6 (12.8) | 25 (26.9) | 30 (30.3) | 7 (16.3) | 7 (20.0) | 3 (10.3) | 72 (24.1) | 69 (25.6) |
| | IV | - | 2 (2.2) | 2 (2.0) | 1 (2.3) | 2 (5.7) | - | 7 (2.3) | 7 (2.6) |
| | Unknown | 1 | - | 6 | 7 | 3 | 4 | 20 | 16 |
| Coronary artery disease, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | No | 301 (85.8) | 394 (87.6) | 570 (92.4) | 489 (87.6) | 412 (89.4) | 302 (90.1) | 2167 (89.5) | 1865 (89.4) |
| | Yes | 50 (14.2) | 56 (12.4) | 47 (7.6) | 69 (12.4) | 49 (10.6) | 33 (9.9) | 254 (10.5) | 221 (10.6) |
| Acute coronary syndrome, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 556 (0) | 460 (0) | 335 (0) | 2418 (0) | 2083 (0) |
| | No | 315 (89.7) | 419 (93.1) | 590 (95.6) | 516 (92.8) | 431 (93.7) | 308 (91.9) | 2264 (93.6) | 1956 (93.9) |
| | Yes | 36 (10.3) | 31 (6.9) | 27 (4.4) | 40 (7.2) | 29 (6.3) | 27 (8.1) | 154 (6.4) | 127 (6.1) |
| | Unknown | - | - | - | 2 | 1 | - | 3 | 3 |
| Carotid Occlusive Disease, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 554 (0) | 457 (0) | 333 (0) | 2411 (0) | 2078 (0) |
| | No | 346 (98.6) | 441 (98.0) | 613 (99.4) | 533 (96.2) | 444 (97.2) | 326 (97.9) | 2357 (97.8) | 2031 (97.7) |

**Table 06 : Clinical History
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|--|-------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| | Yes | 5 (1.4) | 9 (2.0) | 4 (0.6) | 21 (3.8) | 13 (2.8) | 7 (2.1) | 54 (2.2) | 47 (2.3) |
| | Unknown | - | - | - | 4 | 4 | 2 | 10 | 8 |
| PE or DVT, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 557 (0) | 460 (0) | 335 (0) | 2419 (0) | 2084 (0) |
| | No | 345 (98.3) | 439 (97.6) | 609 (98.7) | 540 (96.9) | 451 (98.0) | 328 (97.9) | 2367 (97.9) | 2039 (97.8) |
| | Yes | 6 (1.7) | 11 (2.4) | 8 (1.3) | 17 (3.1) | 9 (2.0) | 7 (2.1) | 52 (2.1) | 45 (2.2) |
| | Unknown | - | - | - | 1 | 1 | - | 2 | 2 |
| Other Thromboemboli sm, n(%) | n (missing) | 351 (0) | 450 (0) | 616 (1) | 0 (558) | 0 (461) | 0 (335) | 1066 (1355) | 1066 (1020) |
| | No | 350 (99.7) | 446 (99.1) | 611 (99.2) | - | - | - | 1057 (99.2) | 1057 (99.2) |
| | Yes | 1 (0.3) | 4 (0.9) | 5 (0.8) | - | - | - | 9 (0.8) | 9 (0.8) |
| Systemic Embolization, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 556 (0) | 460 (0) | 335 (0) | 2418 (0) | 2083 (0) |
| | No | 348 (99.1) | 448 (99.6) | 615 (99.7) | 551 (99.1) | 457 (99.3) | 333 (99.4) | 2404 (99.4) | 2071 (99.4) |
| | Yes | 3 (0.9) | 2 (0.4) | 2 (0.3) | 5 (0.9) | 3 (0.7) | 2 (0.6) | 14 (0.6) | 12 (0.6) |
| | Unknown | - | - | - | 2 | 1 | - | 3 | 3 |
| Coronary Artery Bypass Graft, n(%) | n (missing) | 329 (0) | 424 (0) | 617 (0) | 556 (0) | 461 (0) | 335 (0) | 2393 (0) | 2058 (0) |
| | No | 327 (99.4) | 418 (98.6) | 604 (97.9) | 543 (97.7) | 456 (98.9) | 331 (98.8) | 2352 (98.3) | 2021 (98.2) |
| | Yes | 2 (0.6) | 6 (1.4) | 13 (2.1) | 13 (2.3) | 5 (1.1) | 4 (1.2) | 41 (1.7) | 37 (1.8) |
| | Unknown | 22 | 26 | - | 2 | - | - | 28 | 28 |
| Stroke/TIA, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |

Table 06 : Clinical History
Full Analysis Dataset : SPAIN

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------------------------|-------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| | No | 320 (91.2) | 399 (88.7) | 548 (88.8) | 491 (88.0) | 416 (90.2) | 309 (92.2) | 2163 (89.3) | 1854 (88.9) |
| | Yes | 31 (8.8) | 51 (11.3) | 69 (11.2) | 67 (12.0) | 45 (9.8) | 26 (7.8) | 258 (10.7) | 232 (11.1) |
| Stroke, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 556 (0) | 461 (0) | 335 (0) | 2419 (0) | 2084 (0) |
| | No | 331 (94.3) | 414 (92.0) | 574 (93.0) | 520 (93.5) | 432 (93.7) | 314 (93.7) | 2254 (93.2) | 1940 (93.1) |
| | Yes | 20 (5.7) | 36 (8.0) | 43 (7.0) | 36 (6.5) | 29 (6.3) | 21 (6.3) | 165 (6.8) | 144 (6.9) |
| | Unknown | - | - | - | 2 | - | - | 2 | 2 |
| History of Bleeding, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 556 (0) | 461 (0) | 335 (0) | 2419 (0) | 2084 (0) |
| | No | 332 (94.6) | 443 (98.4) | 606 (98.2) | 535 (96.2) | 450 (97.6) | 330 (98.5) | 2364 (97.7) | 2034 (97.6) |
| | Yes | 19 (5.4) | 7 (1.6) | 11 (1.8) | 21 (3.8) | 11 (2.4) | 5 (1.5) | 55 (2.3) | 50 (2.4) |
| | Unknown | - | - | - | 2 | - | - | 2 | 2 |
| Hypercholester olaemia, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 551 (0) | 459 (0) | 334 (0) | 2411 (0) | 2077 (0) |
| | No | 179 (51.0) | 275 (61.1) | 317 (51.4) | 278 (50.5) | 258 (56.2) | 162 (48.5) | 1290 (53.5) | 1128 (54.3) |
| | Yes | 172 (49.0) | 175 (38.9) | 300 (48.6) | 273 (49.5) | 201 (43.8) | 172 (51.5) | 1121 (46.5) | 949 (45.7) |
| | Unknown | - | - | - | 7 | 2 | 1 | 10 | 9 |
| Diabetes, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | No | 263 (74.9) | 354 (78.7) | 423 (68.6) | 408 (73.1) | 348 (75.5) | 247 (73.7) | 1780 (73.5) | 1533 (73.5) |
| | Type I | 2 (0.6) | 3 (0.7) | 7 (1.1) | 12 (2.2) | 2 (0.4) | 2 (0.6) | 26 (1.1) | 24 (1.2) |
| | Type II | 86 (24.5) | 93 (20.7) | 187 (30.3) | 138 (24.7) | 111 (24.1) | 86 (25.7) | 615 (25.4) | 529 (25.4) |
| Diabetes, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | No | 263 (74.9) | 354 (78.7) | 423 (68.6) | 408 (73.1) | 348 (75.5) | 247 (73.7) | 1780 (73.5) | 1533 (73.5) |
| | Yes | 88 (25.1) | 96 (21.3) | 194 (31.4) | 150 (26.9) | 113 (24.5) | 88 (26.3) | 641 (26.5) | 553 (26.5) |
| Cirrhosis, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 549 (0) | 457 (0) | 334 (0) | 2407 (0) | 2073 (0) |
| | No | 351 (100.0) | 447 (99.3) | 611 (99.0) | 544 (99.1) | 456 (99.8) | 333 (99.7) | 2391 (99.3) | 2058 (99.3) |

Table 06 : Clinical History
Full Analysis Dataset : SPAIN

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|------------------------------|-------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| | Yes | - | 3 (0.7) | 6 (1.0) | 5 (0.9) | 1 (0.2) | 1 (0.3) | 16 (0.7) | 15 (0.7) |
| | Unknown | - | - | - | 9 | 4 | 1 | 14 | 13 |
| Dementia, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 556 (0) | 461 (0) | 335 (0) | 2419 (0) | 2084 (0) |
| | No | 344 (98.0) | 445 (98.9) | 606 (98.2) | 544 (97.8) | 455 (98.7) | 327 (97.6) | 2377 (98.3) | 2050 (98.4) |
| | Yes | 7 (2.0) | 5 (1.1) | 11 (1.8) | 12 (2.2) | 6 (1.3) | 8 (2.4) | 42 (1.7) | 34 (1.6) |
| | Unknown | - | - | - | 2 | - | - | 2 | 2 |
| Hyperthyroidism, n(%) | n (missing) | 351 (0) | 450 (0) | 616 (0) | 554 (0) | 453 (0) | 332 (0) | 2405 (0) | 2073 (0) |
| | No | 345 (98.3) | 442 (98.2) | 612 (99.4) | 545 (98.4) | 449 (99.1) | 327 (98.5) | 2375 (98.8) | 2048 (98.8) |
| | Yes | 6 (1.7) | 8 (1.8) | 4 (0.6) | 9 (1.6) | 4 (0.9) | 5 (1.5) | 30 (1.2) | 25 (1.2) |
| | Unknown | - | - | 1 | 4 | 8 | 3 | 16 | 13 |
| Hypothyroidism, n(%) | n (missing) | 351 (0) | 450 (0) | 616 (0) | 554 (0) | 453 (0) | 332 (0) | 2405 (0) | 2073 (0) |
| | No | 327 (93.2) | 424 (94.2) | 581 (94.3) | 513 (92.6) | 410 (90.5) | 295 (88.9) | 2223 (92.4) | 1928 (93.0) |
| | Yes | 24 (6.8) | 26 (5.8) | 35 (5.7) | 41 (7.4) | 43 (9.5) | 37 (11.1) | 182 (7.6) | 145 (7.0) |
| | Unknown | - | - | 1 | 4 | 8 | 3 | 16 | 13 |
| Vascular Disease, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 556 (2) | 461 (0) | 335 (0) | 2419 (2) | 2084 (2) |
| | No | 287 (81.8) | 391 (86.9) | 557 (90.3) | 476 (85.6) | 415 (90.0) | 296 (88.4) | 2135 (88.3) | 1839 (88.2) |
| | Yes | 64 (18.2) | 59 (13.1) | 60 (9.7) | 80 (14.4) | 46 (10.0) | 39 (11.6) | 284 (11.7) | 245 (11.8) |
| Moderate to Severe CKD, n(%) | n (missing) | 351 (0) | 450 (0) | 617 (0) | 558 (0) | 461 (0) | 335 (0) | 2421 (0) | 2086 (0) |
| | No | 302 (86.0) | 408 (90.7) | 547 (88.7) | 505 (90.5) | 406 (88.1) | 295 (88.1) | 2161 (89.3) | 1866 (89.5) |
| | Yes | 49 (14.0) | 42 (9.3) | 70 (11.3) | 53 (9.5) | 55 (11.9) | 40 (11.9) | 260 (10.7) | 220 (10.5) |

Study ID: TRI08888

GARFIELD: International Registry of Patients Newly Diagnosed with AF

**Table 06 : Clinical History
Full Analysis Dataset : SPAIN**

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|--------------------------------|-------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| Baseline Treatment, n(%) | n (missing) | 344 (0) | 442 (0) | 611 (0) | 554 (0) | 460 (0) | 335 (0) | 2402 (0) | 2067 (0) |
| | VKA | 205 (59.6) | 263 (59.5) | 371 (60.7) | 276 (49.8) | 209 (45.4) | 149 (44.5) | 1268 (52.8) | 1119 (54.1) |
| | VKA+AP | 36 (10.5) | 42 (9.5) | 47 (7.7) | 58 (10.5) | 41 (8.9) | 22 (6.6) | 210 (8.7) | 188 (9.1) |
| | FXA | 2 (0.6) | 5 (1.1) | 15 (2.5) | 51 (9.2) | 75 (16.3) | 78 (23.3) | 224 (9.3) | 146 (7.1) |
| | FXA+AP | 1 (0.3) | 2 (0.5) | 1 (0.2) | 10 (1.8) | 14 (3.0) | 2 (0.6) | 29 (1.2) | 27 (1.3) |
| | DTI | - | 1 (0.2) | 27 (4.4) | 15 (2.7) | 6 (1.3) | 27 (8.1) | 76 (3.2) | 49 (2.4) |
| | DTI+AP | - | - | 5 (0.8) | 3 (0.5) | 2 (0.4) | 1 (0.3) | 11 (0.5) | 10 (0.5) |
| | AP | 78 (22.7) | 80 (18.1) | 88 (14.4) | 82 (14.8) | 50 (10.9) | 30 (9.0) | 330 (13.7) | 300 (14.5) |
| | NONE | 22 (6.4) | 49 (11.1) | 57 (9.3) | 59 (10.6) | 63 (13.7) | 26 (7.8) | 254 (10.6) | 228 (11.0) |
| | Unknown | 7 | 8 | 6 | 4 | 1 | - | 19 | 19 |
| | VKA±AP | 241 (70.1) | 305 (69.0) | 418 (68.4) | 334 (60.3) | 250 (54.3) | 171 (51.0) | 1478 (61.5) | 1307 (63.2) |
| | FXA±AP | 3 (0.9) | 7 (1.6) | 16 (2.6) | 61 (11.0) | 89 (19.3) | 80 (23.9) | 253 (10.5) | 173 (8.4) |
| | DTI±AP | - | 1 (0.2) | 32 (5.2) | 18 (3.2) | 8 (1.7) | 28 (8.4) | 87 (3.6) | 59 (2.9) |
| | FXA/DTI | 2 (0.6) | 6 (1.4) | 42 (6.9) | 66 (11.9) | 81 (17.6) | 105 (31.3) | 300 (12.5) | 195 (9.4) |
| | FXA/DTI+AP | 1 (0.3) | 2 (0.5) | 6 (1.0) | 13 (2.3) | 16 (3.5) | 3 (0.9) | 40 (1.7) | 37 (1.8) |
| | FXA/DTI±AP | 3 (0.9) | 8 (1.8) | 48 (7.9) | 79 (14.3) | 97 (21.1) | 108 (32.2) | 340 (14.2) | 232 (11.2) |
| | AC | 207 (60.2) | 269 (60.9) | 413 (67.6) | 342 (61.7) | 290 (63.0) | 254 (75.8) | 1568 (65.3) | 1314 (63.6) |
| | AC+AP | 37 (10.8) | 44 (10.0) | 53 (8.7) | 71 (12.8) | 57 (12.4) | 25 (7.5) | 250 (10.4) | 225 (10.9) |
| | AC±AP | 244 (70.9) | 313 (70.8) | 466 (76.3) | 413 (74.5) | 347 (75.4) | 279 (83.3) | 1818 (75.7) | 1539 (74.5) |

Table 08: Treatment
Full Analysis Dataset : SPAIN

| | Cohort 1 Retrospective (N=351) (n %) | Cohort 1 Prospective (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|--|---|---|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---|---|
| Anti-platelet (non mutually exclusive groups) | | | | | | | | |
| ADP receptor/P2Y12 inhibitors | 13 (3.7) | 14 (3.1) | 21 (3.4) | 25 (4.5) | 14 (3.0) | 9 (2.7) | 83 (3.4) | 74 (3.5) |
| Cox inhibitors | 21 (6.0) | 24 (5.3) | 1 (0.2) | 26 (4.7) | 2 (0.4) | 3 (0.9) | 56 (2.3) | 53 (2.5) |
| ASA | 66 (18.8) | 66 (14.7) | 125 (20.3) | 115 (20.6) | 93 (20.2) | 44 (13.1) | 443 (18.3) | 399 (19.1) |
| Anticoagulant drugs (non mutually exclusive groups) | | | | | | | | |
| VKA | 245 (69.8) | 312 (69.3) | 423 (68.6) | 335 (60.0) | 250 (54.2) | 171 (51.0) | 1491 (61.6) | 1320 (63.3) |
| FXa | 7 (2.0) | 14 (3.1) | 22 (3.6) | 62 (11.1) | 89 (19.3) | 80 (23.9) | 267 (11.0) | 187 (9.0) |
| DTI | - | 1 (0.2) | 33 (5.3) | 18 (3.2) | 8 (1.7) | 28 (8.4) | 88 (3.6) | 60 (2.9) |
| Heparinoid | 3 (0.9) | 5 (1.1) | 5 (0.8) | 3 (0.5) | 4 (0.9) | 2 (0.6) | 19 (0.8) | 17 (0.8) |
| Heparins | 5 (1.4) | 14 (3.1) | 64 (10.4) | 83 (14.9) | 42 (9.1) | 24 (7.2) | 227 (9.4) | 203 (9.7) |
| Other | - | 1 (0.2) | 1 (0.2) | 2 (0.4) | - | 1 (0.3) | 5 (0.2) | 4 (0.2) |

**Table 09 : Risk scores
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---|--------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| CHADS2 Score | n (missing) | 343 (8) | 438 (12) | 598 (19) | 536 (22) | 439 (22) | 320 (15) | 2331 (90) | 2011 (75) |
| | Mean (SD) | 1.8 (1.1) | 2.0 (1.2) | 2.1 (1.2) | 2.0 (1.1) | 1.9 (1.1) | 1.9 (1.0) | 2.0 (1.1) | 2.0 (1.1) |
| | Median (IQR) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| | Min to Max | 0 to 5 | 0 to 6 | 0 to 6 | 0 to 5 | 0 to 5 | 0 to 5 | 0 to 6 | 0 to 6 |
| CHADS2 score categories, n(%) | n (missing) | 343 (8) | 438 (12) | 598 (19) | 536 (22) | 439 (22) | 320 (15) | 2331 (90) | 2011 (75) |
| | 0 | 27 (7.9) | 26 (5.9) | 31 (5.2) | 22 (4.1) | 23 (5.2) | 16 (5.0) | 118 (5.1) | 102 (5.1) |
| | 1 | 126 (36.7) | 131 (29.9) | 160 (26.8) | 174 (32.5) | 145 (33.0) | 92 (28.8) | 702 (30.1) | 610 (30.3) |
| | 2 | 104 (30.3) | 162 (37.0) | 225 (37.6) | 194 (36.2) | 166 (37.8) | 134 (41.9) | 881 (37.8) | 747 (37.1) |
| | 3 | 66 (19.2) | 69 (15.8) | 114 (19.1) | 87 (16.2) | 68 (15.5) | 56 (17.5) | 394 (16.9) | 338 (16.8) |
| | 4 | 14 (4.1) | 35 (8.0) | 49 (8.2) | 41 (7.6) | 27 (6.2) | 18 (5.6) | 170 (7.3) | 152 (7.6) |
| | 5 | 6 (1.7) | 13 (3.0) | 7 (1.2) | 18 (3.4) | 10 (2.3) | 4 (1.3) | 52 (2.2) | 48 (2.4) |
| | 6 | - | 2 (0.5) | 12 (2.0) | - | - | - | 14 (0.6) | 14 (0.7) |
| CHA2DS2- VASc Score | n (missing) | 343 (8) | 438 (12) | 598 (19) | 534 (24) | 439 (22) | 320 (15) | 2329 (92) | 2009 (77) |
| | Mean (SD) | 3.2 (1.5) | 3.4 (1.6) | 3.5 (1.5) | 3.5 (1.5) | 3.3 (1.4) | 3.4 (1.3) | 3.5 (1.5) | 3.5 (1.5) |
| | Median (IQR) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 4.0 (3.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (3.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) |
| | Min to Max | 0 to 8 | 0 to 8 | 0 to 9 | 0 to 8 | 0 to 7 | 0 to 7 | 0 to 9 | 0 to 9 |
| CHA2DS2- VASc score categories, n(%) | n (missing) | 343 (8) | 438 (12) | 598 (19) | 534 (24) | 439 (22) | 320 (15) | 2329 (92) | 2009 (77) |
| | 0 | 4 (1.2) | 6 (1.4) | 9 (1.5) | 2 (0.4) | 5 (1.1) | 4 (1.3) | 26 (1.1) | 22 (1.1) |
| | 1 | 44 (12.8) | 48 (11.0) | 44 (7.4) | 37 (6.9) | 33 (7.5) | 24 (7.5) | 186 (8.0) | 162 (8.1) |
| | 2 | 71 (20.7) | 74 (16.9) | 108 (18.1) | 92 (17.2) | 83 (18.9) | 44 (13.8) | 401 (17.2) | 357 (17.8) |
| | 3 | 79 (23.0) | 94 (21.5) | 143 (23.9) | 135 (25.3) | 126 (28.7) | 95 (29.7) | 593 (25.5) | 498 (24.8) |
| | 4 | 73 (21.3) | 113 (25.8) | 156 (26.1) | 144 (27.0) | 108 (24.6) | 98 (30.6) | 619 (26.6) | 521 (25.9) |

Table 09 : Risk scores
Full Analysis Dataset : SPAIN

| Variable | Statistics | Cohort 1 Retrospective patients (N=351) (n %) | Cohort 1 Prospective patients (N=450) (n %) | Cohort 2 (N=617) (n %) | Cohort 3 (N=558) (n %) | Cohort 4 (N=461) (n %) | Cohort 5 (N=335) (n %) | Total Prospective patients Cohorts 1 to 5 (N=2421) | Total Prospective patients Cohorts 1 to 4 (N=2086) |
|---------------------------------|--------------|---|---|------------------------------|------------------------------|------------------------------|------------------------------|--|--|
| | 5 | 53 (15.5) | 58 (13.2) | 80 (13.4) | 72 (13.5) | 54 (12.3) | 38 (11.9) | 302 (13.0) | 264 (13.1) |
| | 6-9 | 19 (5.5) | 45 (10.3) | 58 (9.7) | 52 (9.7) | 30 (6.8) | 17 (5.3) | 202 (8.7) | 185 (9.2) |
| HAS-BLED score | n (missing) | 288 (63) | 388 (62) | 477 (140) | 420 (138) | 365 (96) | 248 (87) | 1898 (523) | 1650 (436) |
| | Mean (SD) | 1.5 (0.9) | 1.4 (0.8) | 1.4 (0.9) | 1.6 (0.9) | 1.4 (0.9) | 1.4 (0.9) | 1.5 (0.9) | 1.5 (0.9) |
| | Median (IQR) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.5 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| | Min to Max | 0 to 5 | 0 to 4 | 0 to 4 | 0 to 4 | 0 to 5 | 0 to 5 | 0 to 5 | 0 to 5 |
| HAS-BLED score categories, n(%) | n (missing) | 288 (63) | 388 (62) | 477 (140) | 420 (138) | 365 (96) | 248 (87) | 1898 (523) | 1650 (436) |
| | 0 | 38 (13.2) | 43 (11.1) | 61 (12.8) | 35 (8.3) | 43 (11.8) | 21 (8.5) | 203 (10.7) | 182 (11.0) |
| | 1 | 122 (42.4) | 185 (47.7) | 215 (45.1) | 175 (41.7) | 164 (44.9) | 132 (53.2) | 871 (45.9) | 739 (44.8) |
| | 2 | 95 (33.0) | 121 (31.2) | 146 (30.6) | 153 (36.4) | 119 (32.6) | 68 (27.4) | 607 (32.0) | 539 (32.7) |
| | 3 | 26 (9.0) | 34 (8.8) | 50 (10.5) | 47 (11.2) | 34 (9.3) | 20 (8.1) | 185 (9.7) | 165 (10.0) |
| | 4 | 6 (2.1) | 5 (1.3) | 5 (1.0) | 10 (2.4) | 4 (1.1) | 6 (2.4) | 30 (1.6) | 24 (1.5) |
| | 5 | 1 (0.3) | - | - | - | 1 (0.3) | 1 (0.4) | 2 (0.1) | 1 (0.1) |

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : SPAIN**

| Cohort | CHA2DS2-VASc | VKA | | VKA+AP | | FXA | | FXA+AP | | DTI | | DTI+AP | | AP | | NONE | | UNKNOWN |
|------------------------|--------------|-----|------|--------|------|-----|-----|--------|-----|-----|-----|--------|-----|------|------|------|------|---------|
| | | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n |
| Cohort 1 retrospective | 0 | - | - | - | - | - | - | - | - | - | - | - | - | 2 | 50 | 2 | 50 | - |
| | 1 | 21 | 47.7 | 2 | 4.5 | 2 | 4.5 | - | - | - | - | - | - | 11 | 25 | 8 | 18.2 | - |
| | 2 | 41 | 59.4 | 6 | 8.7 | - | - | - | - | - | - | - | - | 15 | 21.7 | 7 | 10.1 | 2 |
| | 3 | 44 | 55.7 | 14 | 17.7 | - | - | - | - | - | - | - | - | 20 | 25.3 | 1 | 1.3 | - |
| | 4 | 49 | 69 | 5 | 7 | - | - | 1 | 1.4 | - | - | - | - | 13 | 18.3 | 3 | 4.2 | 2 |
| | 5 | 36 | 69.2 | 4 | 7.7 | - | - | - | - | - | - | - | - | 11 | 21.2 | 1 | 1.9 | 1 |
| | 6-9 | 10 | 58.8 | 5 | 29.4 | - | - | - | - | - | - | - | 2 | 11.8 | - | - | 2 | |
| Cohort 1 prospective | 0 | 4 | 66.7 | - | - | - | - | - | - | - | - | - | - | 1 | 16.7 | 1 | 16.7 | - |
| | 1 | 20 | 42.6 | 4 | 8.5 | - | - | 2 | 4.3 | - | - | - | - | 12 | 25.5 | 9 | 19.1 | 1 |
| | 2 | 44 | 59.5 | 7 | 9.5 | 1 | 1.4 | - | - | - | - | - | - | 12 | 16.2 | 10 | 13.5 | - |
| | 3 | 55 | 58.5 | 11 | 11.7 | 2 | 2.1 | - | - | - | - | - | - | 18 | 19.1 | 8 | 8.5 | - |
| | 4 | 67 | 61.5 | 12 | 11 | 1 | 0.9 | - | - | - | - | - | - | 12 | 11 | 17 | 15.6 | 4 |
| | 5 | 41 | 70.7 | 3 | 5.2 | - | - | - | - | - | - | - | - | 12 | 20.7 | 2 | 3.4 | - |
| | 6-9 | 26 | 61.9 | 4 | 9.5 | 1 | 2.4 | - | - | 1 | 2.4 | - | - | 10 | 23.8 | - | - | 3 |
| Cohort 2 | 0 | 1 | 11.1 | - | - | - | - | - | - | - | - | - | - | 3 | 33.3 | 5 | 55.6 | - |
| | 1 | 21 | 47.7 | 1 | 2.3 | - | - | - | - | 2 | 4.5 | 2 | 4.5 | 6 | 13.6 | 12 | 27.3 | - |
| | 2 | 70 | 66 | 9 | 8.5 | 2 | 1.9 | - | - | 3 | 2.8 | - | - | 17 | 16 | 5 | 4.7 | 2 |
| | 3 | 87 | 61.7 | 9 | 6.4 | 4 | 2.8 | - | - | 9 | 6.4 | 1 | 0.7 | 22 | 15.6 | 9 | 6.4 | 2 |
| | 4 | 102 | 65.8 | 12 | 7.7 | 6 | 3.9 | 1 | 0.6 | 6 | 3.9 | - | - | 19 | 12.3 | 9 | 5.8 | 1 |
| | 5 | 47 | 58.8 | 7 | 8.8 | 2 | 2.5 | - | - | 4 | 5 | 1 | 1.3 | 10 | 12.5 | 9 | 11.3 | - |
| | 6-9 | 32 | 56.1 | 8 | 14 | 1 | 1.8 | - | - | 2 | 3.5 | 1 | 1.8 | 10 | 17.5 | 3 | 5.3 | 1 |
| Cohort 3 | 0 | 1 | 50 | - | - | - | - | - | - | - | - | - | - | 1 | 50 | - | - | - |
| | 1 | 12 | 32.4 | 1 | 2.7 | 3 | 8.1 | - | - | 1 | 2.7 | - | - | 11 | 29.7 | 9 | 24.3 | - |
| | 2 | 53 | 57.6 | 3 | 3.3 | 6 | 6.5 | 1 | 1.1 | 3 | 3.3 | - | - | 16 | 17.4 | 10 | 10.9 | - |
| | 3 | 77 | 57.5 | 11 | 8.2 | 9 | 6.7 | 2 | 1.5 | 4 | 3 | - | - | 19 | 14.2 | 12 | 9 | 1 |
| | 4 | 70 | 49.6 | 13 | 9.2 | 14 | 9.9 | 4 | 2.8 | 5 | 3.5 | 1 | 0.7 | 15 | 10.6 | 19 | 13.5 | 3 |

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : SPAIN

| Cohort | CHA2DS2-VASc | VKA | | VKA+AP | | FXA | | FXA+AP | | DTI | | DTI+AP | | AP | | NONE | | UNKNOWN |
|---|--------------|-----|------|--------|------|-----|------|--------|-----|-----|------|--------|-----|----|------|------|------|---------|
| | | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n |
| | 5 | 32 | 44.4 | 14 | 19.4 | 9 | 12.5 | 1 | 1.4 | 1 | 1.4 | 2 | 2.8 | 8 | 11.1 | 5 | 6.9 | - |
| | 6-9 | 26 | 50 | 11 | 21.2 | 4 | 7.7 | 1 | 1.9 | 1 | 1.9 | - | - | 8 | 15.4 | 1 | 1.9 | - |
| Cohort 4 | 0 | 4 | 80 | - | - | 1 | 20 | - | - | - | - | - | - | - | - | - | - | - |
| | 1 | 9 | 27.3 | 1 | 3 | 9 | 27.3 | - | - | 2 | 6.1 | - | - | 3 | 9.1 | 9 | 27.3 | - |
| | 2 | 46 | 55.4 | 6 | 7.2 | 9 | 10.8 | 2 | 2.4 | - | - | 2 | 2.4 | 4 | 4.8 | 14 | 16.9 | - |
| | 3 | 67 | 53.6 | 4 | 3.2 | 21 | 16.8 | 8 | 6.4 | 1 | 0.8 | - | - | 11 | 8.8 | 13 | 10.4 | 1 |
| | 4 | 52 | 48.1 | 12 | 11.1 | 16 | 14.8 | 2 | 1.9 | - | - | - | - | 14 | 13 | 12 | 11.1 | - |
| | 5 | 17 | 31.5 | 10 | 18.5 | 9 | 16.7 | 2 | 3.7 | 2 | 3.7 | - | - | 10 | 18.5 | 4 | 7.4 | - |
| | 6-9 | 7 | 23.3 | 7 | 23.3 | 7 | 23.3 | - | - | - | - | - | - | 5 | 16.7 | 4 | 13.3 | - |
| Cohort 5 | 0 | - | - | - | - | 2 | 50 | - | - | - | - | - | - | 2 | 50 | - | - | - |
| | 1 | 9 | 37.5 | - | - | 5 | 20.8 | - | - | 3 | 12.5 | - | - | 5 | 20.8 | 2 | 8.3 | - |
| | 2 | 17 | 38.6 | 2 | 4.5 | 14 | 31.8 | - | - | 4 | 9.1 | - | - | 3 | 6.8 | 4 | 9.1 | - |
| | 3 | 47 | 49.5 | 5 | 5.3 | 25 | 26.3 | - | - | 5 | 5.3 | 1 | 1.1 | 7 | 7.4 | 5 | 5.3 | - |
| | 4 | 45 | 45.9 | 6 | 6.1 | 17 | 17.3 | 1 | 1 | 11 | 11.2 | - | - | 8 | 8.2 | 10 | 10.2 | - |
| | 5 | 16 | 42.1 | 4 | 10.5 | 10 | 26.3 | 1 | 2.6 | 2 | 5.3 | - | - | 2 | 5.3 | 3 | 7.9 | - |
| | 6-9 | 7 | 41.2 | 5 | 29.4 | 2 | 11.8 | - | - | 2 | 11.8 | - | - | - | - | 1 | 5.9 | - |
| Total Prospective patients Cohorts 1 to 5 | 0 | 10 | 38.5 | - | - | 3 | 11.5 | - | - | - | - | - | - | 7 | 26.9 | 6 | 23.1 | - |
| | 1 | 71 | 38.4 | 7 | 3.8 | 17 | 9.2 | 2 | 1.1 | 8 | 4.3 | 2 | 1.1 | 37 | 20 | 41 | 22.2 | 1 |
| | 2 | 230 | 57.6 | 27 | 6.8 | 32 | 8 | 3 | 0.8 | 10 | 2.5 | 2 | 0.5 | 52 | 13 | 43 | 10.8 | 2 |
| | 3 | 333 | 56.5 | 40 | 6.8 | 61 | 10.4 | 10 | 1.7 | 19 | 3.2 | 2 | 0.3 | 77 | 13.1 | 47 | 8 | 4 |
| | 4 | 336 | 55 | 55 | 9 | 54 | 8.8 | 8 | 1.3 | 22 | 3.6 | 1 | 0.2 | 68 | 11.1 | 67 | 11 | 8 |
| | 5 | 153 | 50.7 | 38 | 12.6 | 30 | 9.9 | 4 | 1.3 | 9 | 3 | 3 | 1 | 42 | 13.9 | 23 | 7.6 | - |
| | 6-9 | 98 | 49.5 | 35 | 17.7 | 15 | 7.6 | 1 | 0.5 | 6 | 3 | 1 | 0.5 | 33 | 16.7 | 9 | 4.5 | 4 |

**Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : SPAIN**

| Cohort | CHA2DS2-VASc | VKA | | VKA+AP | | FXA | | FXA+AP | | DTI | | DTI+AP | | AP | | NONE | | UNKNOWN | |
|----------------------|--------------|-----|------|--------|------|-----|-----|--------|-----|-----|-----|--------|-----|----|------|------|------|---------|--|
| | | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | |
| Total | 0 | 10 | 45.5 | - | - | 1 | 4.5 | - | - | - | - | - | - | 5 | 22.7 | 6 | 27.3 | - | |
| Prospective patients | | | | | | | | | | | | | | | | | | | |
| Cohorts 1 to 4 | | | | | | | | | | | | | | | | | | | |
| | 1 | 62 | 38.5 | 7 | 4.3 | 12 | 7.5 | 2 | 1.2 | 5 | 3.1 | 2 | 1.2 | 32 | 19.9 | 39 | 24.2 | 1 | |
| | 2 | 213 | 60 | 25 | 7 | 18 | 5.1 | 3 | 0.8 | 6 | 1.7 | 2 | 0.6 | 49 | 13.8 | 39 | 11 | 2 | |
| | 3 | 286 | 57.9 | 35 | 7.1 | 36 | 7.3 | 10 | 2 | 14 | 2.8 | 1 | 0.2 | 70 | 14.2 | 42 | 8.5 | 4 | |
| | 4 | 291 | 56.7 | 49 | 9.6 | 37 | 7.2 | 7 | 1.4 | 11 | 2.1 | 1 | 0.2 | 60 | 11.7 | 57 | 11.1 | 8 | |
| | 5 | 137 | 51.9 | 34 | 12.9 | 20 | 7.6 | 3 | 1.1 | 7 | 2.7 | 3 | 1.1 | 40 | 15.2 | 20 | 7.6 | - | |
| | 6-9 | 91 | 50.3 | 30 | 16.6 | 13 | 7.2 | 1 | 0.6 | 4 | 2.2 | 1 | 0.6 | 33 | 18.2 | 8 | 4.4 | 4 | |

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : SPAIN**

| Cohort | HAS-BLED | VKA | | VKA+AP | | FXA | | FXA+AP | | DTI | | DTI+AP | | AP | | NONE | | UNKNOWN | |
|---------------------------|----------|-----|------|--------|------|-----|------|--------|-----|-----|-----|--------|-----|----|------|------|------|---------|---|
| | | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | |
| Cohort 1 retrospective | 0 | 28 | 75.7 | - | - | 1 | 2.7 | - | - | - | - | - | - | - | - | - | 8 | 21.6 | 1 |
| | 1 | 96 | 79.3 | 5 | 4.1 | 1 | 0.8 | - | - | - | - | - | - | 14 | 11.6 | 5 | 4.1 | 1 | |
| | 2 | 44 | 46.8 | 13 | 13.8 | - | - | - | - | - | - | - | - | 34 | 36.2 | 3 | 3.2 | 1 | |
| | 3 | 10 | 38.5 | 5 | 19.2 | - | - | - | - | - | - | - | - | 11 | 42.3 | - | - | - | |
| | 4-9 | 1 | 16.7 | 4 | 66.7 | - | - | - | - | - | - | - | - | 1 | 16.7 | - | - | 1 | |
| Cohort 1 prospective | 0 | 29 | 67.4 | - | - | - | - | - | - | - | - | - | - | - | - | 14 | 32.6 | - | |
| | 1 | 141 | 76.6 | 8 | 4.3 | 2 | 1.1 | 1 | 0.5 | - | - | - | - | 13 | 7.1 | 19 | 10.3 | 1 | |
| | 2 | 56 | 48.7 | 20 | 17.4 | 2 | 1.7 | 1 | 0.9 | 1 | 0.9 | - | - | 28 | 24.3 | 7 | 6.1 | 6 | |
| | 3 | 5 | 14.7 | 5 | 14.7 | - | - | - | - | - | - | - | - | 20 | 58.8 | 4 | 11.8 | - | |
| | 4-9 | 1 | 20 | 1 | 20 | - | - | - | - | - | - | - | - | 3 | 60 | - | - | - | |
| Cohort 2 | 0 | 50 | 83.3 | - | - | 1 | 1.7 | - | - | 2 | 3.3 | - | - | - | - | 7 | 11.7 | 1 | |
| | 1 | 156 | 72.6 | 5 | 2.3 | 7 | 3.3 | - | - | 13 | 6 | 1 | 0.5 | 11 | 5.1 | 22 | 10.2 | - | |
| | 2 | 71 | 49 | 18 | 12.4 | 4 | 2.8 | 1 | 0.7 | 2 | 1.4 | 2 | 1.4 | 35 | 24.1 | 12 | 8.3 | 1 | |
| | 3 | 17 | 34.7 | 12 | 24.5 | 2 | 4.1 | - | - | 1 | 2 | - | - | 16 | 32.7 | 1 | 2 | 1 | |
| | 4-9 | - | - | 1 | 25 | - | - | - | - | 1 | 25 | - | - | 2 | 50 | - | - | 1 | |
| Cohort 3 | 0 | 21 | 60 | - | - | 2 | 5.7 | - | - | 1 | 2.9 | - | - | - | - | 11 | 31.4 | - | |
| | 1 | 126 | 72 | 1 | 0.6 | 16 | 9.1 | 1 | 0.6 | 7 | 4 | - | - | 10 | 5.7 | 14 | 8 | - | |
| | 2 | 57 | 38 | 24 | 16 | 14 | 9.3 | 6 | 4 | 3 | 2 | 2 | 1.3 | 35 | 23.3 | 9 | 6 | 3 | |
| | 3 | 12 | 25.5 | 9 | 19.1 | 4 | 8.5 | 3 | 6.4 | - | - | 1 | 2.1 | 13 | 27.7 | 5 | 10.6 | - | |
| | 4-9 | 2 | 20 | 6 | 60 | - | - | - | - | - | - | - | - | 2 | 20 | - | - | - | |
| Cohort 4 | 0 | 21 | 48.8 | - | - | 13 | 30.2 | - | - | 2 | 4.7 | - | - | - | - | 7 | 16.3 | - | |
| | 1 | 103 | 62.8 | 3 | 1.8 | 26 | 15.9 | 3 | 1.8 | 2 | 1.2 | 1 | 0.6 | 3 | 1.8 | 23 | 14 | - | |
| | 2 | 37 | 31.4 | 15 | 12.7 | 19 | 16.1 | 9 | 7.6 | 1 | 0.8 | 1 | 0.8 | 24 | 20.3 | 12 | 10.2 | 1 | |
| | 3 | 9 | 26.5 | 9 | 26.5 | 2 | 5.9 | 1 | 2.9 | - | - | - | - | 10 | 29.4 | 3 | 8.8 | - | |
| | 4-9 | 1 | 20 | 2 | 40 | - | - | - | - | - | - | - | - | 1 | 20 | 1 | 20 | - | |

**Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : SPAIN**

| Cohort | HAS-BLED | VKA | | VKA+AP | | FXA | | FXA+AP | | DTI | | DTI+AP | | AP | | NONE | | UNKNOWN |
|---|----------|-----|------|--------|------|-----|------|--------|-----|-----|------|--------|-----|-----|------|------|------|---------|
| | | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n |
| Cohort 5 | 0 | 8 | 38.1 | - | - | 7 | 33.3 | - | - | 3 | 14.3 | - | - | - | - | 3 | 14.3 | - |
| | 1 | 65 | 49.2 | 1 | 0.8 | 41 | 31.1 | - | - | 10 | 7.6 | - | - | 8 | 6.1 | 7 | 5.3 | - |
| | 2 | 29 | 42.6 | 8 | 11.8 | 13 | 19.1 | - | - | 3 | 4.4 | 1 | 1.5 | 10 | 14.7 | 4 | 5.9 | - |
| | 3 | 6 | 30 | 2 | 10 | 3 | 15 | 2 | 10 | 2 | 10 | - | - | 2 | 10 | 3 | 15 | - |
| | 4-9 | 1 | 14.3 | 3 | 42.9 | - | - | - | - | - | - | - | - | 3 | 42.9 | - | - | - |
| Total Prospective patients Cohorts 1 to 5 | 0 | 129 | 63.9 | - | - | 23 | 11.4 | - | - | 8 | 4 | - | - | - | - | 42 | 20.8 | 1 |
| Total Prospective patients Cohorts 1 to 4 | 1 | 591 | 67.9 | 18 | 2.1 | 92 | 10.6 | 5 | 0.6 | 32 | 3.7 | 2 | 0.2 | 45 | 5.2 | 85 | 9.8 | 1 |
| | 2 | 250 | 41.9 | 85 | 14.3 | 52 | 8.7 | 17 | 2.9 | 10 | 1.7 | 6 | 1 | 132 | 22.1 | 44 | 7.4 | 11 |
| | 3 | 49 | 26.6 | 37 | 20.1 | 11 | 6 | 6 | 3.3 | 3 | 1.6 | 1 | 0.5 | 61 | 33.2 | 16 | 8.7 | 1 |
| | 4-9 | 5 | 16.1 | 13 | 41.9 | - | - | - | - | 1 | 3.2 | - | - | 11 | 35.5 | 1 | 3.2 | 1 |
| | 0 | 121 | 66.9 | - | - | 16 | 8.8 | - | - | 5 | 2.8 | - | - | - | - | 39 | 21.5 | 1 |
| Total Prospective patients Cohorts 1 to 4 | 1 | 526 | 71.3 | 17 | 2.3 | 51 | 6.9 | 5 | 0.7 | 22 | 3 | 2 | 0.3 | 37 | 5 | 78 | 10.6 | 1 |
| | 2 | 221 | 41.9 | 77 | 14.6 | 39 | 7.4 | 17 | 3.2 | 7 | 1.3 | 5 | 0.9 | 122 | 23.1 | 40 | 7.6 | 11 |
| | 3 | 43 | 26.2 | 35 | 21.3 | 8 | 4.9 | 4 | 2.4 | 1 | 0.6 | 1 | 0.6 | 59 | 36 | 13 | 7.9 | 1 |
| | 4-9 | 4 | 16.7 | 10 | 41.7 | - | - | - | - | 1 | 4.2 | - | - | 8 | 33.3 | 1 | 4.2 | 1 |
| | 0 | 121 | 66.9 | - | - | 16 | 8.8 | - | - | 5 | 2.8 | - | - | - | - | 39 | 21.5 | 1 |

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : SPAIN**

| Variable | Statistics | Cohort 1 Prospective patients (N=305) (n %) | Cohort 2 (N=418) (n %) | Cohort 3 (N=334) (n %) | Cohort 4 (N=250) (n %) | Total Prospective patients Cohorts 1 to 4 (N=1307) |
|--------------------|--------------|---|------------------------------|------------------------------|------------------------------|--|
| TTR value, n(%) | n (missing) | 178 (127) | 251 (167) | 215 (119) | 146 (104) | 790 (517) |
| | <65 | 109 (61.2) | 136 (54.2) | 123 (57.2) | 91 (62.3) | 459 (58.1) |
| | >=65 | 69 (38.8) | 115 (45.8) | 92 (42.8) | 55 (37.7) | 331 (41.9) |
| TTR | n (missing) | 178 (127) | 251 (167) | 215 (119) | 146 (104) | 790 (517) |
| | Mean (SD) | 57.8 (23.2) | 60.5 (20.1) | 58.2 (21.2) | 55.5 (22.5) | 58.4 (21.6) |
| | Median (IQR) | 58.3 (42.4 to 73.5) | 62.5 (48.6 to 74.7) | 60.5 (45.6 to 73.7) | 59.9 (43.8 to 71.0) | 60.5 (45.7 to 73.7) |
| | Min to Max | 0.0 to 100.0 | 0.0 to 100.0 | 0.0 to 100.0 | 0.0 to 98.4 | 0.0 to 100.0 |
| INR value, n(%) | n | 2072 | 3537 | 3063 | 2185 | 10857 |
| | 2-3 | 1070 (51.6) | 1867 (52.8) | 1524 (49.8) | 1044 (47.8) | 5505 (50.7) |
| | <2 | 599 (28.9) | 1005 (28.4) | 932 (30.4) | 660 (30.2) | 3196 (29.4) |
| | >3 | 403 (19.4) | 665 (18.8) | 607 (19.8) | 481 (22.0) | 2156 (19.9) |
| INR | n | 2072 | 3537 | 3063 | 2185 | 10857 |
| | Mean (SD) | 2.5 (1.0) | 2.5 (0.9) | 2.5 (1.0) | 2.6 (1.1) | 2.5 (1.0) |
| | Median (IQR) | 2.3 (1.9 to 2.9) | 2.3 (1.9 to 2.8) | 2.3 (1.9 to 2.9) | 2.3 (1.9 to 2.9) | 2.3 (1.9 to 2.9) |
| | Min to Max | 0.8 to 9.9 | 0.8 to 15.5 | 0.9 to 10.0 | 0.9 to 10.0 | 0.8 to 15.5 |

**Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : SPAIN**

| Outcome | Cause | N | Events | Event rate /100 person-years | 95% CI |
|-----------------------------|-------------------------------------|------|--------|------------------------------------|----------------|
| All-cause death | | 2086 | 93 | 4.64 | (3.78 to 5.68) |
| | Cardiovascular death | 2086 | 36 | 1.80 | (1.30 to 2.49) |
| | Non-Cardiovascular death | 2086 | 40 | 1.99 | (1.46 to 2.72) |
| | Undetermined cause | 2086 | 17 | 0.85 | (0.53 to 1.36) |
| Stroke/SE | | 2086 | 28 | 1.40 | (0.97 to 2.03) |
| Major bleed | | 2086 | 26 | 1.30 | (0.89 to 1.92) |
| Acute coronary syndrome | | 2086 | 16 | 0.80 | (0.49 to 1.31) |
| Congestive Heart Failure | | 2086 | 41 | 2.07 | (1.52 to 2.81) |

**Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : SPAIN**

| | | SPAIN | | |
|----------------------------------|-----------------------------|-------|--------|-------|
| Outcome | Cause | N | Events | % |
| Cardiovascular causes | Myocardial infarction | 36 | 1 | 2.78 |
| | Ischaemic stroke | 36 | 5 | 13.89 |
| | Congestive heart failure | 36 | 16 | 44.44 |
| | Sudden or unwitnessed death | 36 | 2 | 5.56 |
| | Other | 36 | 12 | 33.33 |
| Non-cardiovascular causes | Accidental / trauma | 40 | 4 | 10.00 |
| | Respiratory failure | 40 | 8 | 20.00 |
| | Infection/sepsis | 40 | 10 | 25.00 |
| | Malignancy | 40 | 11 | 27.50 |
| | Other | 40 | 7 | 17.50 |

**Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :SPAIN**

| OUTCOME | SPAIN | | |
|--|-------|--------|------|
| | N | Events | % |
| Stroke(not including systemic embolism) | 2086 | 24 | 1.15 |
| Primary Ischemic Stroke | 2086 | 20 | 0.96 |
| <i>of which secondary hemorrhagic ischemic</i> | 2086 | 2 | 0.10 |
| Primary intracerebral hemorrhage* | 2086 | 1 | 0.05 |
| <i>Intracerebral</i> | 2086 | 1 | 0.05 |
| Undetermined | 2086 | 3 | 0.14 |

**Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : SPAIN**

| CHA2DS2-VASc | N | Person-Years | Events | Event rate /100 person-years | 95% CI |
|--------------|-----|--------------|--------|------------------------------------|-----------------|
| 0 | 22 | 20.81 | 1 | 4.81 | (0.68 to 34.12) |
| 1 | 162 | 158.93 | 2 | 1.26 | (0.32 to 5.03) |
| 2 | 357 | 346.64 | 11 | 3.17 | (1.76 to 5.73) |
| 3 | 498 | 479.53 | 17 | 3.55 | (2.20 to 5.70) |
| 4+ | 970 | 924.65 | 58 | 6.27 | (4.85 to 8.11) |
| Unknown | 77 | 75.07 | 4 | 5.33 | (2.00 to 14.20) |

**Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : SPAIN**

| CHA2DS2-VASc | N | Person-Years | Events | Event rate /100 person-years | 95% CI |
|--------------|-----|--------------|--------|------------------------------------|----------------|
| 0 | 22 | 20.81 | 0 | - | - |
| 1 | 162 | 158.93 | 0 | - | - |
| 2 | 357 | 346.36 | 1 | 0.29 | (0.04 to 2.05) |
| 3 | 498 | 476.59 | 7 | 1.47 | (0.70 to 3.08) |
| 4+ | 970 | 918.04 | 20 | 2.18 | (1.41 to 3.38) |
| Unknown | 77 | 75.07 | 0 | - | - |

**Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : SPAIN**

| CHA2DS2-VASc | N | Person-Years | Events | Event rate /100 person-years | 95% CI |
|--------------|-----|--------------|--------|------------------------------------|-----------------|
| 0 | 22 | 20.81 | 0 | - | - |
| 1 | 162 | 158.93 | 0 | - | - |
| 2 | 357 | 344.71 | 3 | 0.87 | (0.28 to 2.70) |
| 3 | 498 | 476.20 | 8 | 1.68 | (0.84 to 3.36) |
| 4+ | 970 | 919.17 | 13 | 1.41 | (0.82 to 2.44) |
| Unknown | 77 | 74.16 | 2 | 2.70 | (0.68 to 10.78) |